Business
Total Voting Rights
Total Voting Rights.
About this update from Aura Renewable Acquisitions Plc
[{"type":"text","content":"\n Ardana PLC\n21 December 2006\n\n\n Ardana plc (LSE: ARA) - voting rights and capital\n\nEdinburgh, UK, 21 December 2006; In conformity with the Transparency\nDirective's transitional provision 6 we would like to notify the market of the\nfollowing:\n\nAs at 21 December 2006, the issued share capital and voting rights of Ardana plc\nare as follows:\n\nArdana plc's capital consists of 65,268,939 ordinary 1p shares with voting\nrights attached of one vote per ordinary share of which 12,681 ordinary shares\nare held in Treasury.\n\nTherefore, the total number of voting rights in Ardana plc is 65,256,258.\n\nThe above figure (65,256,258) may be used by shareholders as the denominator for\nthe calculations by which they will determine if they are required to notify\ntheir interest in, or a change to their interest in, Ardana plc under the FSA's\nDisclosure and Transparency Rules.\n\n\nEnquiries\n\nFor more information contact:\n\nMaureen Lindsay + 44 (0) 131 226 8550\nArdana\n\nJulia Phillips/John Gilbert +44 (0)20 7831 3113\nFinancial Dynamics\n(corporate and financial media relations)\n\n\n\nAbout Ardana\n\n\nArdana plc is a pharmaceutical company focused on the discovery, development and\nmarketing of innovative products to improve human reproductive health, a $25.5\nbillion market*.\n\nSince its foundation, Ardana has maintained a broad and balanced portfolio to\nmanage risk and actively pursues product and technology in-licensing and\nout-licensing to maintain a robust pipeline.\n\nArdana's four lead products are summarised below:\n\n\n • Emselex(R), a once a day treatment for the symptoms of overactive bladder\n which Ardana has exclusive UK marketing and promotion rights and is being\n distributed in collaboration with Novartis Pharmaceuticals UK Limited;\n • StriantTM SR, a testosterone replacement therapy that has been launched by\n Ardana through its own sales force in the UK and through marketing partners\n in certain European countries, as a treatment for men with confirmed\n hypogonadism;\n • Invicorp, an injectable combination drug treatment for erectile\n dysfunction, for which Ardana has marketing and manufacturing rights in\n Europe;\n • Teverelix LA, in development for three initial indications (prostate\n cancer, BPH and endometriosis);\n • Testosterone Cream, a transdermal testosterone delivery system ...